<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52222">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02426333</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN AKF-14.07</org_study_id>
    <nct_id>NCT02426333</nct_id>
  </id_info>
  <brief_title>Optimizing Abiraterone Therapy</brief_title>
  <acronym>OPTIMUM</acronym>
  <official_title>Optimizing Abiraterone (Zytiga®) Therapy by Exploring the Relation Between an Early Biomarker ‐ Drug Exposure ‐ as a Predictor for Drug Response in Patients With mCRPC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore whether early abiraterone exposure is related to
      treatment response in patients with metastatic castration resistant prostate cancer.
      Furthermore to explore the relation between biomarkers and treatment response and drug
      exposure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>abiraterone AUC</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>biomarkers: relation between biomarkers and treatment response</measure>
    <time_frame>6 months</time_frame>
    <description>relation between biomarkers and treatment response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biomarker reduction</measure>
    <time_frame>6 months</time_frame>
    <description>To explore the if reduction in biomarkers is related to treatment response after three and six months</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Metastatic Castration Resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Abiraterone Acetate</arm_group_label>
    <description>abiraterone treatment, 1000mg, tablets, once daily, treatment is not adapted for the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Abiraterone Acetate</intervention_name>
    <description>Exclusively determine pharmacokinetics and pharmacodynamics of abiraterone for the indication according to the drug label (CRPC)</description>
    <arm_group_label>Abiraterone Acetate</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for abiraterone concentrations and also blood samples to assess biomarkers
      (some contain DNA)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male patients with metastatic castration resistant prostate cancer who are asymptomatic or
        mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is
        not yet clinically indicated
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with metastatic castration resistant prostate cancer who are asymptomatic or
             mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy
             is not yet clinically indicated

          -  Age ≥18 years

          -  Feasible to collect blood samples from

          -  Life expectancy of &gt; 6 months

          -  Measurable disease

          -  Able and willing to give written informed consent prior to screening and enrollment

        Exclusion Criteria:

          -  other anticancer therapies

          -  potent CYP3A4 inducers

          -  herbal medicine that could interfere with abiraterone exposure
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nielka van Erp, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jack Schalken, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nielka van Erp, PharmD, PhD</last_name>
    <phone>+31243616405</phone>
    <email>nielka.vanerp@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mette Benoist, PharmD</last_name>
    <phone>+31243616405</phone>
    <email>mette.benoist@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tineke Smilde, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rik Somford, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Rik Somford, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud UMC</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nielka van Erp, PharmD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Nielka van Erp, PharmD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jack Schalken, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>March 27, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
